Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · IEX Real-Time Price · USD
46.61
-1.07 (-2.24%)
At close: Jul 19, 2024, 4:00 PM
45.68
-0.93 (-2.00%)
Pre-market: Jul 22, 2024, 6:18 AM EDT
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for AGIO stock have an average target of 50.67, with a low estimate of 46 and a high estimate of 53. The average target predicts an increase of 8.71% from the current stock price of 46.61.
Analyst Consensus: Buy
* Price targets were last updated on Jun 13, 2024.
Analyst Ratings
The average analyst rating for AGIO stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 17, 2024 |
| JP Morgan | JP Morgan | Hold Initiates $46 | Hold | Initiates | $46 | -1.31% | Jun 13, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $33 → $53 | Hold | Maintains | $33 → $53 | +13.71% | Jun 4, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $44 → $53 | Buy | Maintains | $44 → $53 | +13.71% | Jun 4, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $29 → $33 | Hold | Maintains | $29 → $33 | -29.20% | May 3, 2024 |
Financial Forecast
Revenue This Year
45.51M
from 26.82M
Increased by 69.66%
Revenue Next Year
133.63M
from 45.51M
Increased by 193.64%
EPS This Year
-2.43
from -6.33
EPS Next Year
-5.75
from -2.43
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 60.8M | 286.7M | 365.9M | 593.9M | 995.5M |
| Avg | 45.5M | 133.6M | 231.3M | 443.2M | 699.3M |
| Low | 35.0M | 62.5M | 109.2M | 335.5M | 542.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 126.7% | 529.9% | 173.8% | 156.8% | 124.6% |
| Avg | 69.7% | 193.6% | 73.1% | 91.6% | 57.8% |
| Low | 30.4% | 37.4% | -18.3% | 45.0% | 22.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.14 | -3.30 | -1.38 | 1.05 | 5.72 |
| Avg | -2.43 | -5.75 | -4.88 | -1.87 | 1.25 |
| Low | -6.75 | -6.73 | -7.04 | -3.15 | -1.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.